Blog
Drug Target Encyclopedia Series (4) — CD8
Release Time：
2025-12-03 15:16
CD8 is a transmembrane glycoprotein best known for its role as a co-receptor on cytotoxic T lymphocytes (CTLs), where it recognizes antigen-presenting MHC class I molecules. Beyond its textbook role in adaptive immunity, CD8 has emerged as a crucial biomarker and therapeutic target in cancer immunotherapy, infectious disease control, and autoimmune modulation.
In oncology, CD8+ T cell infiltration in tumors is strongly correlated with better prognosis and therapeutic response—earning it a central role in immune checkpoint blockade (ICB) strategies. High CD8+ T cell presence often predicts responsiveness to PD-1/PD-L1 inhibitors and other immunotherapies.
Emerging Strategies Involving CD8 Modulation While CD8 itself isn't the direct target of most therapies, it plays a critical role in enabling therapeutic efficacy:
- Adoptive T cell therapies – Including TCR-T and CAR-T cells, often engineered to enrich CD8+ cytotoxic activity.
- Checkpoint inhibitors – Designed to unleash CD8+ T cells from exhaustion and enhance tumor killing.
- CD8+ T cell enhancers – Novel cytokines, adjuvants, and metabolic modulators to improve CD8+ T cell activation and persistence.
In infectious diseases like HIV and COVID-19, CD8+ T cells are indispensable for viral clearance. Conversely, in autoimmune conditions, aberrant CD8+ T cell activity may contribute to tissue damage, highlighting their dual-edged nature.
As the next generation of immunotherapies continues to evolve, CD8 remains at the forefront—whether as a biomarker of efficacy, a target for enhancement, or a tool for cellular engineering.
Need CD8+ tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898